Merck's ADC Success: Insights from Global Trial Results

Merck's ADC Success: Insights from Global Trial Results

This article examines Merck's successful antibody-drug conjugates (ADCs) and their global trial results, highlighting key insights for investors and BD teams. The October 2023 deal with Daiichi Sankyo—worth up to $22 billion in total milestone payments—reshaped the oncology competitive map overnight, triggering a wave of repositioning across pharma boardrooms.

Key Takeaways

• Merck's three co-developed DXd ADCs—patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan—have posted clinically meaningful response rates across multiple solid tumor indications, narrowing the risk profile of a pipeline category historically plagued by narrow therapeutic windows.
• The Daiichi Sankyo collaboration gives Merck access to a validated payload-linker platform that ZS Associates describes as "comparatively de-risked" relative to other oncology modalities—a metric that directly shapes portfolio allocation models for probability of technical and regulatory success (PTRS).
• Regulatory tailwinds from both the FDA and EMA are accelerating ADC development timelines. The FDA's Oncology Center of Excellence has issued multiple guidance documents specific to ADC development, while the EMA's accelerated assessment pathway has been triggered for several ADCs in the past 24 months, signaling institutional comfort with the modality.

The October 2023 Deal That Shifted the ADC Landscape

On October 19, 2023, Merck & Co. and Daiichi Sankyo announced a global development and commercialization collaboration covering three clinical-stage DXd antibody-drug conjugates. Under the terms disclosed in the joint press release, Merck agreed to pay Daiichi Sankyo $4 billion upfront, with an additional $1.5 billion in continuation payments over 24 months, plus up to $16.5 billion in contingent milestones tied to specific development and commercial achievements.

The three assets—patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd, targeting B7-H3), and raludotatug deruxtecan (R-DXd, targeting CDH6)—cover distinct antigen targets that collectively address large segments of the oncology market beyond the HER2 space where Daiichi Sankyo's earlier ADC, Enhertu, established dominance. Daiichi Sankyo retains rights in Japan and will manufacture the products globally, while Merck books sales everywhere else and shoulders the majority of development costs going forward.

What made this deal structurally unusual was its breadth. Rather than licensing a single asset or a single target, Merck effectively acquired an option on Daiichi Sankyo's entire next-wave ADC pipeline—a maneuver competing BD teams have since scrambled to replicate. The upfront payment, while substantial, looks calibrated against the addressable market: the three programs collectively target indications with a combined global patient population exceeding 500,000 annually, according to epidemiologic data cited in analyst reports following the announcement.

Clinical Momentum: Trial Results That Justify the Price Tag

The data supporting these assets continues to accumulate. Patritumab deruxtecan, the most advanced of the three, has shown activity in EGFR-mutated non-small cell lung cancer (NSCLC) patients who have progressed on osimertinib and platinum-based chemotherapy—a population with few remaining options. An FDA biologics license application for this NSCLC indication was accepted for priority review in December 2023, with a Prescription Drug User Fee Act (PDUFA) goal date set for June 2024. That regulatory milestone carries implications for the broader ADC class: it would represent the first HER3-directed therapy to reach the U.S. market.

Ifinatamab deruxtecan, aimed at B7-H3, has generated response data in small-cell lung cancer (SCLC) and castration-resistant prostate cancer that analysts at several investment banks have flagged as potentially registrational. Raludotatug deruxtecan, the CDH6-targeting asset, remains earlier in development but has shown signals in ovarian cancer—an indication where ADC approaches have historically struggled to achieve a therapeutic index wide enough to support approval.

Much of the confidence across this portfolio rests on the DXd platform itself. Daiichi Sankyo's proprietary linker technology has demonstrated a consistent ability to deliver payload at high drug-to-antibody ratios while maintaining a manageable toxicity profile, a balance that earlier-generation ADC platforms frequently failed to achieve. This technical moat was central to the Merck deal and remains a key variable competitor BD teams must price into any rival collaboration or acquisition.

Regulatory Frameworks Are Bending Toward Acceleration

Both the FDA and EMA have moved in recent years to streamline ADC development pathways. The FDA's guidance on clinical pharmacology considerations for ADCs, first issued in draft form in 2022 and finalized in early 2024, clarified expectations around exposure-response analyses, immunogenicity testing, and the role of pharmacokinetic modeling in dose selection. This document removed a significant source of regulatory uncertainty that had previously slowed ADC programs at the Phase 2/3 transition.

On the European side, the EMA's Committee for Medicinal Products for Human Use (CHMP) has increasingly accepted single-arm trial data for ADC accelerated assessments in indications with high unmet need, mirroring the FDA's posture and creating a more harmonized global regulatory environment. For BD teams managing multi-regional development plans, this harmonization reduces the cost and complexity of running parallel regulatory strategies across the Atlantic.

Both agencies continue to scrutinize the ocular, pulmonary, and hematologic toxicity signals that have historically accompanied ADC development, however. The FDA's Oncologic Drugs Advisory Committee has convened multiple times in the past 18 months to discuss risk-benefit assessments for individual ADC candidates, and that level of public scrutiny signals that while the pathway is clearer, the bar for safety documentation has not been lowered.

Implications for Pharma BD and Regulatory Teams

The Merck-Daiichi Sankyo collaboration altered the opportunity set for business development groups across the industry. The deal structure—a broad platform partnership rather than a single-asset license—established a template that several companies have since attempted to replicate with remaining ADC platform owners. The scarcity of validated linker-payload platforms with late-stage clinical data means that remaining BD targets are commanding premium valuations, a dynamic already reflected in biotech public markets since late 2023.

For regulatory teams, the evolving framework at both the FDA and EMA demands proactive engagement. The FDA's clinical pharmacology guidance for ADCs specifies data package expectations that affect trial design decisions as early as Phase 1. Teams that treat these guidances as static reference documents risk submission delays; the regulatory landscape for ADCs is moving quickly enough that a six-month lag in awareness can translate to a missed market window.

The EMA's accelerated assessment procedure has been updated with specific references to oncology products demonstrating exceptional therapeutic innovation, language that fits the ADC profile. BD teams negotiating territorial split rights should factor in the differential between U.S. and EU approval timelines, which, while narrowing, still averages four to six months.

Future Milestones Worth Watching

Several catalysts over the next 12 to 18 months will determine whether the Merck gamble pays off at the scale implied by the upfront commitment. The June 2024 PDUFA date for patritumab deruxtecan in EGFR-mutant NSCLC is the nearest binary event. Beyond that, Phase 3 readouts for ifinatamab deruxtecan in SCLC—an indication where existing ADC data has already attracted competitor interest—will test the breadth of the platform's applicability. Raludotatug deruxtecan's Phase 2 ovarian cancer data, expected in late 2024, will either validate the CDH6 hypothesis or narrow the addressable market projections that BD analysts have modeled.

Competitively, the next wave of ADC licensing deals will be priced against these data readouts. The gap between what Merck paid and what a late-2024 deal commands will serve as a real-time measure of whether the DXd platform delivered on the promise that the upfront payment implied.

FAQ

Related coverage

• AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial